GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Bought by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 6.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,713 shares of the company’s stock after purchasing an additional 5,412 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in GE HealthCare Technologies were worth $7,445,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the stock. Darwin Wealth Management LLC acquired a new position in shares of GE HealthCare Technologies in the third quarter worth $31,000. Continuum Advisory LLC raised its stake in GE HealthCare Technologies by 101.8% in the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares during the last quarter. Bank of Jackson Hole Trust purchased a new position in GE HealthCare Technologies in the 4th quarter valued at about $32,000. OFI Invest Asset Management acquired a new stake in shares of GE HealthCare Technologies during the 4th quarter worth about $34,000. Finally, Avion Wealth grew its holdings in shares of GE HealthCare Technologies by 497.4% during the fourth quarter. Avion Wealth now owns 460 shares of the company’s stock worth $35,000 after buying an additional 383 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently issued reports on GEHC shares. Wells Fargo & Company raised their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Citigroup lifted their price objective on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and increased their target price for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. Finally, The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and lifted their price target for the company from $85.00 to $100.00 in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $98.75.

GE HealthCare Technologies Trading Up 0.6 %

GEHC opened at $81.97 on Friday. The firm has a market capitalization of $37.48 billion, a P/E ratio of 18.93, a P/E/G ratio of 3.19 and a beta of 1.13. The firm’s 50 day moving average is $87.26 and its 200-day moving average is $86.12. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. The firm had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. Analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.